26 results about "Menopause" patented technology

An Artificial Intelligence (AI) system trained by a plurality of training data. The AI system is trained by relationships between a time to final menstrual period and ratios between follicle-stimulating hormone levels and estradiol levels, anti-mullerian hormone, race, cholesterol levels, and a presence of one or more contraceptives. The AI system is configured to accept data from only one sample from a user as input and generate a prediction of a time to final menstrual period for the user as output.

The application of unilateral or bilateral permanent prostheses to the labium majus in the external genitalia of women for reconstructive and aesthetic purposes may make it appear fuller. The labium majus may lose its fullness and symmetry due to menopause, rapid weight gain and loss, traumas, cancers, and infectious diseases. Aesthetic interventions (e.g., hyaluronic acid filler injection and fat grafting) aiming to provide the labium majus with fullness have become very popular in recent years. The hyaluronic acid filler is used for reconstructive purposes to achieve fullness in labium majus. However, the maximum amount that can be injected is 3 mL, which is often insufficient for the desired outcome and its effect lasts for a maximum of 1 year. Autologous fat grafting is administered by taking 18–120 mL of fat from patients themselves; however, its effect usually lasts 1 to 4 years. The application of a prosthesis will provide labium majus with fullness and this effect will be long-lasting. The outer edge of the prosthesis is convex and the inner edge is concave. In male genitalia, prostheses have been used since 1950 to provide the testicles with fullness. Scientific studies have shown that these prostheses positively affect self-confidence and body perception indices in men.

Disclosed herein are compositions comprising two or more sleep-inducing agonists and / or a sleep-inducing antagonist. The compositions are for promoting healthy sleep quality and treating, ameliorating, preventing, or reducing one or more symptoms associated with menopause. Also described herein are methods utilizing the aforementioned compositions.

It is an object to provide a novel technology that can improve a female menopausal symptom. Provided is an agent for improving a female menopausal symptom, containing a lactobacillus strain that is Lactobacillus gasseri CP2305 strain (accession number: FERM BP-11331), a processed product of the lactobacillus strain, or an extract thereof.

The invention relates to the technical field of medical care informatics, in particular to an auxiliary screening system and method for osteoporosis of elderly women, and the method comprises the steps: obtaining the menopause time and age of each elderly woman, and dividing clusters through clustering, analyzing the menopausal time change volatility of the elderly women in each cluster, the internal distribution proximity concentration degree of the elderly women and the data uniformity of the elderly women so as to determine the actual expansion demand degree of each cluster, so that the data of the elderly women is expanded, and a big data bone detection model is constructed; the method is used for monitoring whether elderly women have osteoporosis or not. According to the method, the demenopausal time and the age of the elderly women are clustered to divide the clusters, the actual expansion demand degree of each cluster is analyzed and determined, each cluster is expanded, and the expanded data is used for constructing a more perfect big data bone detection model, so that the bone detection accuracy is improved, and the bone detection efficiency is improved. Therefore, the accuracy of auxiliary detection of osteoporosis of elderly women is improved.

The system according to this embodiment aims to manage hormone balance in order to effectively support the mental and physical health of women in menopause. [Solution] The system according to the embodiment comprises a collection unit, an analysis unit, a management unit, and a provision unit. The collection unit collects user data. The analysis unit analyzes the data collected by the collection unit. The management unit manages hormone balance based on the data analyzed by the analysis unit. The provision unit provides the user with the results managed by the management unit.

Disclosed herein are compositions for treating, ameliorating, preventing, or reducing the symptoms associated with menopause and / or hot flashes. The compositions disclosed herein comprise a curcumin composition, a green tea extract composition, and a phycocyanin composition that act as neurokinin 3 receptor antagonists. Also described herein are methods utilizing the aforementioned compositions.

Disclosed herein are compositions comprising two or more sleep-inducing agonists and / or a sleep-inducing antagonist. The compositions are for promoting healthy sleep quality and treating, ameliorating, preventing, or reducing one or more symptoms associated with menopause. Also described herein are methods utilizing the aforementioned compositions.

This specification describes a pharmaceutical composition of a melatonin receptor agonist for use in tissues outside the CNS. Also described herein are methods of using the pharmaceutical compositions described herein to improve the menopause system and to improve reproductive outcomes in polycystic ovary syndrome, endometriosis, chemotherapy-induced ovarian dysfunction, and inflammatory and metabolic diseases.

The present disclosure relates to aqueous topical formulations comprising at least one TRPV1 antagonist and at least one specific plant extract. Also disclosed herein are methods of treating at least one symptom of menopause comprising topically administering an effective amount of the formulations disclosed.

An Artificial Intelligence (AI) system trained by a plurality of training data. The AI system is trained by relationships between a time to final menstrual period and ratios between follicle-stimulating hormone levels and estradiol levels, race, cholesterol levels, and a presence of one or more contraceptives. The AI system is configured to accept data from only one sample from a user as input and generate a prediction of a time to final menstrual period for the user as output.

The present application provides a kind of female menopause conditioning essential oil composition and its preparation process, belong to conditioning menopausal essential oil technical field;Its preparation method includes: preparation black cohosh extract nanocomposite;Preparation composite essential oil microcapsule;Preparation essential oil composition.The present application by whey protein isolate and carboxymethyl starch sodium are dissolved respectively, then heated stirring is mixed, make two preliminary combination by electrostatic attraction, then join compound essential oil, after being processed into composite emulsion by homogenization and ultrasonic, can significantly increase the specific surface area of microcapsule, provide more adsorption sites, then by transglutaminase catalysis glutamine and lysine crosslinking reaction between whey protein isolate molecules, form three-dimensional network skeleton, while the carboxyl of carboxymethyl starch sodium can be combined with the amino group of whey protein isolate by ionic bond, fill network gap, so as to effectively improve the embedding rate of compound essential oil.

The invention discloses a hip joint prosthesis structure optimization method based on female menopausal factors. The method comprises the following steps: S1, geometric modeling of a hip joint prosthesis; s2, establishing a multi-stage female menopausal factor femur-prosthesis finite element model; and S3, optimizing the evaluation indexes and the structure of the hip joint prosthesis. According to the invention, the influence of staged change of female postmenopausal on stiffness change and life of the hip joint prosthesis is studied, and a method for optimizing the internal local pore parameter structure and the prosthesis stiffness of the hip joint prosthesis is provided for the hip joint prosthesis, so that a more accurate experimental result can be obtained, a stress shielding effect is avoided, and the reliability of the hip joint prosthesis is improved. The long-term stability, the safety and the service life of the prosthesis are improved.

The invention relates to the technical field of medicines, in particular to novel application of kidney-tonifying and bone-strengthening capsules. The intervention effect of the kidney-tonifying and bone-strengthening capsules on castrated rats is evaluated through systematic pharmacodynamic experiments. Experimental results show that the kidney-tonifying and bone-strengthening capsule can significantly improve the level of estradiol (E2) in serum, improve metabolic disorders and inhibit abnormal weight increase caused by castration; therefore, the kidney-tonifying and bone-strengthening capsule can be applied to preparation of a medicine for regulating the in-vivo estrogen level of a menopausal female or a castration female; or the composition is applied to preparation of medicines for preventing abnormal weight growth after female menopause or castration. In addition, Micro-CT and histopathologic analysis prove that the kidney-tonifying and bone-strengthening capsule can effectively recover the bone density and improve the bone microstructure; the kidney-tonifying and bone-strengthening capsule can be applied to preparation of medicines for preventing or treating menopausal or castration female osteoporosis, provides a new Chinese patent medicine option for medicine treatment of osteoporosis, and enriches clinical medication choices.

Provided herein are methods of treating symptoms associated with menopause, perimenopause and / or post-menopause in a subject in need thereof by administering to the subject compositions comprising a triple reuptake inhibitor (e.g., Compound 1).

To provide a sexual intercourse aid which can be worn on the male genital organ of a person suffering from erectile dysfunction due to climacteric disorders or the like, thereby assisting sexual intercourse.SOLUTION: A sexual intercourse aid 1 comprises: a main body 2 which extends in a first direction X and is formed with an arrangement portion 21 in which a penis A of a male genital organ is to be arranged; a holding portion 3 which extends from an end portion 22 of the main body 2 in a second direction Y substantially orthogonal to the first direction X, in order to keep the penis A arranged in the arrangement portion 21; and a contact portion 4 which rises from a tip end side 23 of the main body 2 so as to contact a glans B in the first direction X. The holding portion 3 is formed of a flexible resin, and has its extended tip end side 41 open, and the contact portion 4 is formed of a flexible resin, bulges toward the first direction X when viewed from the second direction Y, and has a shape recessed on the holding portion 3 side.SELECTED DRAWING: Figure 2

The invention relates to a calcium-containing food supplement that differs from its counterparts in that it contains Lysine amino acid, which contributes to the absorption of calcium, and Arginine amino acids, which enable the utilisation of calcium in the metabolic process, which is generally developed for use in supporting bone and bone development metabolism, in order to support the prevention of Osteoporosis, Maleostasis, seen in women after menopause; in adult men, to contribute positively to the solution of problems in the absorption and utilisation of calcium that occur in bone metabolism with aging; To protect dental health and in dental implant treatment, to ensure the stability of the implant by surrounding the implant surface of the bone tissue; to ensure that children have stronger bones and, to the extent permitted by genetic factors, longer bones and therefore taller stature at the developmental age; Depending on various factors, to support the absorption and transport of calcium in skeletal problems, to support faster and better union of bone fractures.

The present invention relates to new uses of a 5-HT4 receptor agonist, specifically Isopropyl-3 - { 5- [ 1 -(3 - methoxypropyl) piperidin-4-yl] - [ 1,3,4] oxadiazol-2-yl } - 1 H- indazole (Compound- 1) or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment and behavioural and psychological symptoms of dementia such as apathy / indifference, agitation, aggression, depression, anxiety, irritability / lability, dysphoria, aberrant motor behaviour, delusions, hallucinations, elation / euphoria, psychosis, disinhibition, sleep and night time behaviour disorders or appetite and eating disorders. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.

The present invention is directed to methods for treating dry eye comprising administering indole-3-carbinol, a metabolite thereof, a derivative thereof, a salt thereof or a hydrate thereof to a subject in need thereof. The present invention is further directed to treating vulvovaginal dryness comprising administering indole-3-carbinol, a metabolite thereof, a derivative thereof, a salt thereof or a hydrate thereof to a subject in need thereof. The present invention is further directed to treating cataracts and / or glaucoma comprising administering an ophthalmic composition comprising indole-3-carbinol, a metabolite, a derivative, a salt or a hydrate thereof to a subject in need thereof, wherein the cataracts and / or glaucoma are associated with menopause.

The present invention relates to new uses of a pure 5-HT6 receptor antagonist, specifically 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salts thereof, for the treatment of dementia due to menopause, senile dementia, vascular dementia, chemotherapy-induced cognitive impairment and behavioral changes in dementia such as agitation, aggression, depression, anxiety, psychosis, disinhibition, or sleep disturbances. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.

The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component.The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.

The invention discloses an oral liquid preparation containing eldecalciferol. The eldecalciferol oral liquid is prepared from the following components in parts by weight: 20 to 50 parts of eldecalciferol, 5 to 10 parts of polyoxyethylene hydrogenated castor oil, 10 to 15 parts of medium-chain fatty acid triglyceride, 10 to 15 parts of tocopherol, 10 to 15 parts of ethanol, 5 to 10 parts of purified water, 1 to 2 parts of citric acid, 1 to 2 parts of sorbitol, 0.5 to 1.0 part of a flavoring agent and 0.2 to 0.5 part of a bacteriostatic agent. The invention also provides a preparation method of the oral liquid preparation. The prepared oral liquid preparation containing eldecalciferol has an obvious treatment effect on osteoporosis symptoms caused by female menopause.

Compositions comprising two or more sleep-inducing agonists and / or one sleep-inducing antagonist are disclosed herein. These compositions promote healthy sleep quality and treat, improve, prevent, or reduce one or more symptoms associated with menopause. Methods using the aforementioned compositions are also described herein.

Methods for modulating nerve activity to treat menopause and associated symptoms are disclosed. The methods include placing a neuromodulation device in communication with a target site of the autonomic nervous system or parasympathetic nervous system. The neuromodulation device comprises at least a modulating component, at least one controller, and at least one connecting element. The device delivers a stimulation paradigm to the target site, modulating nerve activity to induce a therapeutic effect, thereby treating menopause and associated symptoms.

The present invention relates to a composition for alleviating male menopause symptoms, the composition containing probiotics selected from among eight novel strains of probiotics, that is, two strains of Lactis paracasei, four strains of Lactis plantarum, one strain of Lymosilactobacillus fermentum, and one strain of Streptococcus thermophilus. The probiotics are characterized by enhancing the secretion of the male hormone testosterone, and enhancing the expression of a gene, selected from among 3β-hydroxysteroid dehydrogenase I (3β-HSD-I), 3β-hydroxysteroid dehydrogenase VI (3β-HSD-VI), androgen receptor (AR), and steroidogenic acute regulatory protein (StAR), involved in testosterone secretion.

Determine the user's stage of menopause. [Solution] The information processing device 100 includes a bleeding information acquisition unit 111 that acquires bleeding information indicating the user's menstrual or irregular bleeding status, a periodicity information acquisition unit 112 that acquires information indicating the menstrual periodicity based on the status of the user's multiple menstrual periods included in the bleeding information, a menopausal stage determination unit 113 that determines the menopausal stage indicating the user's stage of menopause based at least on the information on the user's menstrual periodicity, and a display control unit 114 that controls the display of the determined menopausal stage.